Cabozantinib, sold under the brand-name Cabometyx and Cometriq, is a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. It was discovered and developed by Exelixis Inc.
This report contains market size and forecasts of Cabozantinib in global, including the following market information:
Global Cabozantinib Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Cabozantinib Market Sales, 2017-2022, 2023-2028, (Tons)
Global top five Cabozantinib companies in 2021 (%)
The global Cabozantinib market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Capsule Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cabozantinib include Exelixis, Tecoland Corporation, Fermion Oy, Sun Pharmaceutical Industries Limit, MSN Laboratories Pvt Ltd, Shanghai Hope Chem, Hetero Drugs Limited, Huateng Pharmaceutical Co. and Bio Nova Pharmaceuticals Private Limited and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cabozantinib manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cabozantinib Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Tons)
Global Cabozantinib Market Segment Percentages, by Type, 2021 (%)
Capsule
Tablet
Global Cabozantinib Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Tons)
Global Cabozantinib Market Segment Percentages, by Application, 2021 (%)
Medullary Thyroid Cancer Treatment
Second Line Treatment for Renal Cell Carcinoma
Global Cabozantinib Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Tons)
Global Cabozantinib Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cabozantinib revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Cabozantinib revenues share in global market, 2021 (%)
Key companies Cabozantinib sales in global market, 2017-2022 (Estimated), (Tons)
Key companies Cabozantinib sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Exelixis
Tecoland Corporation
Fermion Oy
Sun Pharmaceutical Industries Limit
MSN Laboratories Pvt Ltd
Shanghai Hope Chem
Hetero Drugs Limited
Huateng Pharmaceutical Co.
Bio Nova Pharmaceuticals Private Limited
AlchemyPharm